TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01913444
Drug: Recombinant Antithrombin
Normalized name: ANTITHROMBIN III,RECOMBINANT
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00543049
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year
Study: NCT00543049
Drug: SUNITINIB
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib, oral, 37,5 mg once daily continuously, up to one year
Study: NCT03292744
Drug: Alfacalcidol
Normalized name: Alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfacalcidol 0,5 mcg
Study: NCT00002723
Drug: suramin
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
Study: NCT00002723
Drug: suramin
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
Study: NCT00002723
Drug: Suramin
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
Study: NCT00475969
Drug: duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00988429
Drug: 800 mg QD Eslicarbazepine acetate
Normalized name: eslicarbazepine acetate 800 MG
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
Study: NCT00988429
Drug: 1200 mg QD Eslicarbazepine acetate
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
Study: NCT00000940
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000940
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00000940
Drug: Amprenavir
Normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00000940
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000940
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03110640
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.
Study: NCT01074229
Drug: Drug .5% Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: .5% ropivacaine 20 mls on each side of abdomen
Study: NCT01074229
Drug: 20 cc of 0.25% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
Study: NCT03555617
Drug: TD-1473
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral capsule/tablet, QD
Study: NCT03555617
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral solution, QD
Study: NCT02197494
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 320mg tablets
Study: NCT02163499
Drug: Sodium Zirconium Cyclosilicate
Normalized name: sodium zirconium cyclosilicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
Study: NCT01107717
Drug: metformin, glyburide and glargine
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c \< 6.5%
Study: NCT03536520
Drug: ACETAZOLAMIDE oral capsule
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
Study: NCT03369119
Drug: Montelukast 4 Mg Oral Granule
Normalized name: montelukast 4 mg oral granule
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01412398
Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet
Normalized name: lanthanum carbonate Chewable Tablet
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in CAPD who have received Fosrenol for hyperphosphatemia
Study: NCT01118429
Drug: Oxybutynin
Normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
Study: NCT00559871
Drug: fipamezole
Normalized name: Fipamezole
DrugBank: Fipamezole (DB06585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fipamezole in Zydis formulation three times per day for up to 28 days
Study: NCT04054245
Drug: LOXL2 Inhibitor PAT-1251
Normalized name: Fibrinolysis inhibitor
DrugBank: PAT-1251 (DB16735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01587703
Drug: GSK525762
Normalized name: Bet inhibitor gsk525762
DrugBank: Molibresib (DB16239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Begin at Dose Level 1 and increase up to 2 fold
Study: NCT01714947
Drug: [^14C]-alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[\^14C\]-alisertib oral solution
Study: NCT01714947
Drug: alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib enteric coated tablets
Study: NCT00421135
Drug: ZIO-201
Normalized name: Zioptan
DrugBank: Tafluprost (DB08819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.
Study: NCT00370747
Drug: Ecabet
Normalized name: ecabet
DrugBank: Ecabet (DB05265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution 2.83%
Study: NCT00370747
Drug: Ecabet
Normalized name: ecabet
DrugBank: Ecabet (DB05265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution 3.70%
Study: NCT00463957
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00463957
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00878904
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00878904
Drug: panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00101296
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00365599
Drug: suberoylanilide hydroxamic acid (SAHA, Vorinostat)
Normalized name: Suberoylanilide hydroxamic acid
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
Study: NCT00365599
Drug: tamoxifen citrate (Tamoxifen)
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
Study: NCT01181193
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. 75 mg/m2/day for entire period of radiotherapy~2. 150-200 mg/m2/day for 5 days every 28 days, 6 cycles total
Study: NCT01181193
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU started 1 week before commencing radiotherapy and discontinued immediately after completing last chemotherapy cycle
Study: NCT02068079
Drug: Vemurafenib and Trientine
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01309802
Drug: onabotulinum toxin type-A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
Study: NCT02259959
Drug: Tiotropium, fixed dose, solution for oral inhalation
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03944499
Drug: FS-1502
Normalized name: FS-1502
DrugBank: FS-1502 (DB19287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-Escalation Phase (Phase 1a)： FS-1502 dose-escalation will be proceeded on standard 3+3 design with starting dose of 0.1 mg/kg, IV, once per 28 days, 28 days as a cycle in the V1.2 and V2.0 regimens; IV, once per 21 days, 21 days as a cycle in the V3.0 regimens..~Dose level 1: 0.1 mg/kg; Dose level 2: 0.2 mg/kg; Dose level 3: 0.4 mg/kg; Dose level 4: 0.6 mg/kg; Dose level 5: 0.8 mg/kg; Dose level 6: 1.0 mg/kg; Dose level 7: 1.3 mg/kg. If 1.3mg/kg is still tolerated safely and in line with linear kinetic characteristics, and combined with the results of PK, PD, safety and effectiveness, a comprehensive assessment is made to determine whether to continue the dose escalating. The subsequent dose increase ratio is 33% (the dose increase ratio can be adjusted according to the previous data results) until MTD or RP2D.~Dose-expansion Phase (Phase 1b) : RP2D determined in phase 1a, IV.
Study: NCT01320683
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01289054
Drug: Tasigna
Normalized name: Tasigna
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01320683
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01289054
Drug: Gleevec
Normalized name: Gleevec
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02099656
Drug: Lebrikizumab
Normalized name: Lebrikizumab
DrugBank: Lebrikizumab (DB11914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
Study: NCT02099656
Drug: Inhaled corticposteroids (ICS)
Normalized name: abiraterone and corticosteroids
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
Study: NCT02829099
Drug: JNJ-64457107
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64457107 administered by IV infusion on Day 1 and 14 of a 28-day cycle.
Study: NCT00376259
Drug: telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600mg/day oral tablet for 96 weeks
Study: NCT00376259
Drug: adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg of adefovir by mouth once daily
Study: NCT04779047
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.
Study: NCT04779047
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.
Study: NCT04779047
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 800 mg once.
Study: NCT04779047
Drug: Lopinavir/ Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
Study: NCT04779047
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 36 mg at day 1,3 and 6.
Study: NCT02321371
Drug: Lactulose + Rifaximin
Normalized name: Rifaximin
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route
Study: NCT02321371
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuation of Lactulose therapy for further 48 hours.
Study: NCT02005484
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 mg/kg initial dose, followed by 2 mg/kg
Study: NCT01636700
Drug: Tramadol 2mg/kg
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg/kg
Study: NCT01636700
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline solution- 1 dose
Study: NCT04387773
Drug: GOCOVRI
Normalized name: Gocovri
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will have gait and balance baseline assessment and then repeat assessment after being on full-dose of GOCOVRI for two weeks. The assessments will include measures of gait, balance and dyskinesia. Participants will also wear body-worn sensors (on wrist, feet and lumbar area) during daily-life for seven days to quantify mobility.~GOCOVRI will be started at 137mg/day for two weeks and then increased to 274mg/day for two weeks. Participants will repeat baseline assessments and then decrease to a dose of 137mg/day of GOCOVRI for one week, before stopping the medication completely.~All participants will receive GOCOVRI and they will know that they are on study drug. No placebo group.
Study: NCT03214055
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The mannitol has been administered routinely to prevent renal dysfunction in patients undergoing robot-assisted laparoscopic radical prostatectomy. Participants will receive the mannitol as part of routine medical care, and we will evaluate the change in optic nerve sheath diameters before and after mannitol administration.
Study: NCT03034772
Drug: Dorzolamide-timolol
Normalized name: dorzolamide-timolol ophthalmic
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical eye drop (active comparator) used twice daily for study duration
Study: NCT02547025
Drug: rabeprazole+3 antibiotics
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
Study: NCT02547025
Drug: rabeprazole+bismuth+2 antibiotics
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
Study: NCT02547025
Drug: rabeprazole+amox+tetr+levo
Normalized name: rabeprazole, amoxicillin and clarithromycin
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
Study: NCT01642030
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study: NCT01642030
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study: NCT00070161
Drug: donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00010322
Drug: atamestane
Normalized name: Atamestane
DrugBank: Atamestane (DB12194)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00010322
Drug: toremifene
Normalized name: Toremifene
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00516178
Drug: Fish oil emulsion
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA
Study: NCT00516178
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 infusions, perioperative or post-PTCA
Study: NCT00313963
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Magnesium Sulfate (100 mg/Kg, Max 2 gram/dose) 8 hourly.
Study: NCT02660034
Drug: Pamiparib
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01388621
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
Study: NCT01388621
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
Study: NCT01388621
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
Study: NCT01388621
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
Study: NCT01388621
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
Study: NCT03237741
Drug: Reference capsule GDC-0134
Normalized name: calcium carbonate
DrugBank: GDC-0134 (DB17079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.
Study: NCT03237741
Drug: Prototype capsule GDC-0134
Normalized name: calcium carbonate
DrugBank: GDC-0134 (DB17079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.
Study: NCT03237741
Drug: rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.
Study: NCT01493947
Drug: Ivermectin 1% cream
Normalized name: IVERMECTIN 1% CREAM,TOP
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
Study: NCT01493947
Drug: Metronidazole 0.75% cream
Normalized name: METRONIDAZOLE 0.75% CREAM,TOP
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
Study: NCT01126008
Drug: CCRT with weekly docetaxel & cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks
Study: NCT04501354
Drug: Mesenchymal Stem Cell
Normalized name: Human mesenchymal stem cell
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal Stem Cell + NaCl 0,9% 2ml
Study: NCT00015132
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02188745
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.